{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-24-006996","form_type":"8-K","ticker":"BGLC","cik":"0001737523","company_name":"BioNexus Gene Lab Corp","filed_at":"2024-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.409828+00:00","generated_at":"2026-05-30T02:54:17.045211+00:00","sec_items":["3.01","5.02"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioNexus Gene Lab receives Nasdaq delisting notice; appeals with compliance plan including reverse stock split","bullets":["Received delisting notice on Nov 5, 2024 for failing to maintain minimum $1 bid price after two 180-day grace periods ended Nov 4.","Filed appeal on Nov 8, 2024; hearing stays trading suspension pending Panel decision.","Intends to present compliance plan including potential reverse stock split to regain listing compliance.","Appointed Jook Yuen Low as independent director effective Nov 5, assigned to Audit and Nomination committees.","Re-appointed Su-Leng Tan Lee as Secretary and appointed as President; no compensation change."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-24-006996","json":"https://secwatch.observer/filing/0001477932-24-006996.json","markdown":"https://secwatch.observer/filing/0001477932-24-006996.md","text":"https://secwatch.observer/filing/0001477932-24-006996.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737523/000147793224006996/0001477932-24-006996-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737523/000147793224006996/bglc_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:54:17.045211+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0149dd086f","claim":"Su-Leng Tan Lee was appointed as President at BioNexus Gene Lab Corp.","evidence_excerpt":"Additionally, the Board has re-appointed Mr. Su-Leng Tan Lee as Secretary of the Company and has appointed him as President, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737523/000147793224006996/0001477932-24-006996-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed as President"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"1fe5d88c5a","claim":"Jook Yuen Low was appointed as Director at BioNexus Gene Lab Corp.","evidence_excerpt":"On November 5, 2024, the Board of Directors of the Company appointed Ms. Jook Yuen Low as an independent director to the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737523/000147793224006996/0001477932-24-006996-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}